Tempus AI shares rise following BTIG analyst upgrade and Personalis deal

Tempus AI shares experienced significant activity following an analyst upgrade from BTIG Research, which raised its price target from $70 to $80 while maintaining a ‘buy’ rating. The stock saw increased trading volume and a jump in price, marking a strong performance period for the company.

Much of the investor optimism is linked to Tempus AI’s $1.5 billion agreement to acquire Personalis. This acquisition is expected to integrate advanced genetic analysis and sequencing capabilities into Tempus AI’s offerings. Specifically, the company plans to handle gene sequencing for the personalized cancer vaccine being developed by Moderna and Merck, pending FDA approval. This move is viewed by analysts as a potential new ‘pharma services’ revenue stream.

In addition to the price target hike, the company has seen unusual options trading activity, with call option volume increasing by approximately 57% compared to average daily levels. While recent insider activity shows executives selling shares under pre-arranged trading plans, the company’s recent earnings beat consensus estimates.